GeneDx Holdings Corp. WGS
2 targets with a reported result
Releases of the last 3 yearsThe numbers WGS said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $540.00M to $555.00M release Jan 12, 2026
Kept $540.00M to $555.00M release Feb 23, 2026
Lowered $475.00M to $490.00M release May 4, 2026
Kept $475.00M to $490.00M release Aug 3, 2026
Kept $475.00M to $490.00M release Nov 9, 2026
|
– | Not reported yet | |
The company's wordsIssues full year 2026 guidance expecting revenues between $540 and $555 million, with 33-35% exome and genome growth release Jan 12, 2026 Metric Guidance … Revenue $540 to $555 million release Feb 23, 2026 Updating full-year 2026 revenue guidance to $475 to $490 million with exome and genome volume growth of at least 30% release May 4, 2026 Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30% release Aug 3, 2026 Reiterating full year 2026 revenue guidance of $475 to $490 million release Nov 9, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $350.00M to $360.00M release Feb 18, 2025
Raised $400.00M to $415.00M release Jul 29, 2025
Raised $425.00M to $428.00M release Oct 28, 2025
|
$427.54M 10-K filed 2026-02-23 |
Within the range | |
The company's wordsFY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% release Feb 18, 2025 Metric Previous Guidance Updated Guidance … Revenue $400 to $415 million release Jul 29, 2025 Metric Previous Guidance Updated Guidance … Revenue $425 to $428 million release Oct 28, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $220.00M to $230.00M release Feb 20, 2024
Raised $235.00M to $245.00M release Apr 29, 2024
Raised $255.00M to $265.00M release Jul 30, 2024
|
$305.45M 10-K filed 2025-02-20 |
Above the range | |
The company's wordsManagement expects GeneDx to: … Drive full year 2024 revenues between $220 and $230 million; release Feb 20, 2024 “Our team’s successful execution in the first quarter gives us the confidence to raise full year 2024 revenue guidance to between $235-$245 million and reiterate our expectation to reach profitability in 2025.” release Apr 29, 2024 “Our continued organizational focus on execution fueled our strong second quarter results, giving us confidence to raise full year 2024 revenue guidance to between $255-$265 million and reiterate our expectation to reach profitability in the next several quarters,” said Katherine Stueland, President and Chief Executive Officer at GeneDx. release Jul 30, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WGS/export.csv") into a cell.